Anti-CD7 CAR-T Therapy Yields High Response Rate in Acute Leukemia
(MedPage Today) — Donor-derived anti-CD7 chimeric antigen receptor (CAR) T-cell therapy led to complete responses in 18 of 20 patients with relapsed or refractory (r/r) T-cell acute lymphoblastic leukemia (ALL), a first-in-human clinical trial…
Read More
0
